140 related articles for article (PubMed ID: 23180455)
1. SULF2 expression by immunohistochemistry and overall survival in oesophageal cancer: a cohort study.
Lui NS; van Zante A; Rosen SD; Jablons DM; Lemjabbar-Alaoui H
BMJ Open; 2012; 2(6):. PubMed ID: 23180455
[TBL] [Abstract][Full Text] [Related]
2. SULF2 Expression Is a Potential Diagnostic and Prognostic Marker in Lung Cancer.
Lui NS; Yang YW; van Zante A; Buchanan P; Jablons DM; Lemjabbar-Alaoui H
PLoS One; 2016; 11(2):e0148911. PubMed ID: 26882224
[TBL] [Abstract][Full Text] [Related]
3. Sulfatase-2: a prognostic biomarker and candidate therapeutic target in patients with pancreatic ductal adenocarcinoma.
Alhasan SF; Haugk B; Ogle LF; Beale GS; Long A; Burt AD; Tiniakos D; Televantou D; Coxon F; Newell DR; Charnley R; Reeves HL
Br J Cancer; 2016 Sep; 115(7):797-804. PubMed ID: 27560551
[TBL] [Abstract][Full Text] [Related]
4. Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer.
Lim SH; Hong M; Ahn S; Choi YL; Kim KM; Oh D; Ahn YC; Jung SH; Ahn MJ; Park K; Zo JI; Shim YM; Sun JM
Eur J Cancer; 2016 Jan; 52():1-9. PubMed ID: 26623522
[TBL] [Abstract][Full Text] [Related]
5. Expression of the extracellular sulfatase SULF2 is associated with squamous cell carcinoma of the head and neck.
Flowers SA; Zhou X; Wu J; Wang Y; Makambi K; Kallakury BV; Singer MS; Rosen SD; Davidson B; Goldman R
Oncotarget; 2016 Jul; 7(28):43177-43187. PubMed ID: 27223083
[TBL] [Abstract][Full Text] [Related]
6. SULFs in human neoplasia: implication as progression and prognosis factors.
Bret C; Moreaux J; Schved JF; Hose D; Klein B
J Transl Med; 2011 May; 9():72. PubMed ID: 21599997
[TBL] [Abstract][Full Text] [Related]
7. Prognosis of oesophageal adenocarcinoma and squamous cell carcinoma following surgery and no surgery in a nationwide Swedish cohort study.
Kauppila JH; Mattsson F; Brusselaers N; Lagergren J
BMJ Open; 2018 May; 8(5):e021495. PubMed ID: 29748347
[TBL] [Abstract][Full Text] [Related]
8. Expression of the Extracellular Sulfatase
Yang Y; Ahn J; Raghunathan R; Kallakury BV; Davidson B; Kennedy ZB; Zaia J; Goldman R
Front Oncol; 2020; 10():582827. PubMed ID: 33585200
[TBL] [Abstract][Full Text] [Related]
9. Extracellular sulfatases as potential blood-based biomarkers for early detection of lung cancer.
Yang YW; Jablons DM; Lemjabbar-Alaoui H
Exp Lung Res; 2021; 47(6):261-279. PubMed ID: 33908819
[TBL] [Abstract][Full Text] [Related]
10. Human epidermal growth factor receptor-2 in oesophageal cancers: an observational study.
Al-Momani H; Barnes R; El-Hadi A; Shah R; Lewis WG; Edwards P
World J Gastroenterol; 2012 Nov; 18(44):6447-51; discussion p.6450. PubMed ID: 23197890
[TBL] [Abstract][Full Text] [Related]
11. Sulfatase 2 protects hepatocellular carcinoma cells against apoptosis induced by the PI3K inhibitor LY294002 and ERK and JNK kinase inhibitors.
Lai JP; Sandhu DS; Yu C; Moser CD; Hu C; Shire AM; Aderca I; Murphy LM; Adjei AA; Sanderson S; Roberts LR
Liver Int; 2010 Nov; 30(10):1522-8. PubMed ID: 21040406
[TBL] [Abstract][Full Text] [Related]
12. Effect of neoadjuvant chemoradiotherapy on angiogenesis in oesophageal cancer.
McDonnell CO; Bouchier-Hayes DJ; Toomey D; Foley D; Kay EW; Leen E; Walsh TN
Br J Surg; 2003 Nov; 90(11):1373-8. PubMed ID: 14598417
[TBL] [Abstract][Full Text] [Related]
13. Expressions of melanoma-associated antigen A1 as a prognostic factor in Chinese patients with resectable oesophageal squamous cell carcinoma.
Yu Y; Huang C; Li Z; Zhao F; Zhou Y; Li J; Zhu C; Li Q; Zhuang Y; Xu J; Luo J; Chen L; Wang W
Interact Cardiovasc Thorac Surg; 2019 Oct; 29(4):510-516. PubMed ID: 31169876
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemoradiation for patients with advanced oesophageal cancer - which response grading system best impacts prognostic discrimination?
Puetz K; Bollschweiler E; Semrau R; Mönig SP; Hölscher AH; Drebber U
Histopathology; 2019 Apr; 74(5):731-743. PubMed ID: 30636069
[TBL] [Abstract][Full Text] [Related]
15. SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15.
Tessema M; Yingling CM; Thomas CL; Klinge DM; Bernauer AM; Liu Y; Dacic S; Siegfried JM; Dahlberg SE; Schiller JH; Belinsky SA
Oncogene; 2012 Sep; 31(37):4107-16. PubMed ID: 22158045
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of neoadjuvant chemoradiation in cT3 oesophageal cancer - A propensity score matched analysis.
Hölscher AH; Bollschweiler E; Bogoevski D; Schmidt H; Semrau R; Izbicki JR
Eur J Cancer; 2014 Nov; 50(17):2950-7. PubMed ID: 25307749
[TBL] [Abstract][Full Text] [Related]
17. Keratin 17 activates AKT signalling and induces epithelial-mesenchymal transition in oesophageal squamous cell carcinoma.
Liu Z; Yu S; Ye S; Shen Z; Gao L; Han Z; Zhang P; Luo F; Chen S; Kang M
J Proteomics; 2020 Jan; 211():103557. PubMed ID: 31669361
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of G9a and MCM7 in oesophageal squamous cell carcinoma is associated with poor prognosis.
Zhong X; Chen X; Guan X; Zhang H; Ma Y; Zhang S; Wang E; Zhang L; Han Y
Histopathology; 2015 Jan; 66(2):192-200. PubMed ID: 24805087
[TBL] [Abstract][Full Text] [Related]
19. Extracellular Heparan 6-
Yang Y; Ahn J; Edwards NJ; Benicky J; Rozeboom AM; Davidson B; Karamboulas C; Nixon KCJ; Ailles L; Goldman R
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428645
[TBL] [Abstract][Full Text] [Related]
20. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
